CClinicalTrials.gg
CompletedNCT06722326HYDRAPPETUpdated Jan 20, 2025

Hydrogen-rich Water and Appetite in Obesity

An interventional study of Dietary Supplement: Hydrogen-rich water and Dietary Supplement: Control water in Obesity, sponsored by University of Novi Sad, Faculty of Sport and Physical Education. Completed at 1 site in Serbia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by University of Novi Sad, Faculty of Sport and Physical Education · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2024, registered Dec 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main goal of this study is to investigate how dihydrogen supplementation impacts body composition, appetite, quality of life specific to obesity, and levels of the hormone GLP-1 in men and women with obesity. This randomized controlled trial aims to explore whether dihydrogen can improve these health indicators.

Read the detailed description

The primary aim of this randomized controlled trial is to evaluate the effects of dihydrogen supplementation on body composition indices, appetite, obesity-specific quality of life, and circulating GLP-1 levels in obese men and women

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • dihydrogen
  • appetite
  • LDL cholesterol
  • supplementation
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 36 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Novi Sad, Faculty of Sport and Physical Education is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-65 years
  • Body fat > 30% in women and > 25% in men
  • Not physically active
  • Informed consent signed

Exclusion criteria

Exclusion Criteria:

  • Major chronic disease and acute injuries
  • History of dietary supplement use during the past 4 weeks
  • History of obesity pharmaceuticals use during the past 8 weeks
  • No consent to randomization
  • Participation in other studies
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Hydrogen-rich water

    One liter per day of hydrogen rich water

    Dietary Supplement: Dietary Supplement: Hydrogen-rich water

  • Placebo comparator
    Control water

    One liter per day of tap water

    Dietary Supplement: Dietary Supplement: Control water

Interventions

  • Dietary supplementDietary Supplement: Hydrogen-rich water

    Hydrogen-rich water with 12 mg of hydrogen per serving

  • Dietary supplementDietary Supplement: Control water

    Control water with 0 mg of hydrogen per serving

06

What researchers measure

Primary outcomes

  1. Appetite

    Total scores for appetite as assessed by the the Food Cravings Questionnaire (FCQ)

    Time frame: Change from baseline appetite at 8 weeks

Secondary outcomes

  1. Obesity-related quality or life

    Total scores for obesity-related quality of life as assessed by the The Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire

    Time frame: Change from baseline total scores for obesity-related quality of life at 8 weeks

  2. Body fat

    Percentage of body fat as assessed by a multifrequency bioelectrical impedance analyzer

    Time frame: Change from baseline body fat at 8 weeks

  3. Serum GLP-1

    Serum levels of glucagon-like peptide-1 (GLP-1)

    Time frame: Change from baseline GLP-1 at 8 weeks

07

Study locations

1 site
  • Applied Bioenergetics Lab
    Novi Sad, Vojvodina 26000, Serbia
08

References and documents

Publications

  • Korovljev D, Ostojic J, Todorovic N, Ostojic SM. Molecular hydrogen modulates brain glutamate/GABA-glutamine cycle in overweight humans. Arch Med Sci. 2023 Jul 13;19(4):1151-1153. doi: 10.5114/aoms/162938. eCollection 2023. PubMed 37560746 ↗

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in obesity. Data will be coded, with no PHI included. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party.

Supporting information: Study protocol, Sap, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06722326
Lead sponsor
University of Novi Sad, Faculty of Sport and Physical Education
Responsible party
Sergej Ostojic (Professor and Head of the Lab, University of Novi Sad, Faculty of Sport and Physical Education) — Principal investigator
First posted
Dec 9, 2024
Start date
May 15, 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Jan 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion